Updates are available Correction dated 2024-06-05

Article History

Accepted: 27 March 2024

First Online: 13 April 2024

Change Date: 5 June 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s41669-024-00499-2

Declarations

:

: Dawn Lee has provided consultancy services to a number of companies unrelated to possible intervention, comparators, intervention or comparator companies in the RCC appraisal. She was previously employed as the Chief Scientific Officer at Lumanity until September 2022 and is a very small shareholder in Value Demonstration Group (who are the holding company for Lumanity). She has also been a member of Fiecon’s strategic council from November 2023. Darren Burns is employed as an analyst at Delta Hat Limited. He has worked on projects, and for companies, unrelated to possible intervention, comparators, intervention or comparator companies in this RCC appraisal. He has provided consultancy services for Pfizer on a technology unrelated to RCC, and Servier on multilocular cystic RCC (MCRCC), which is not considered a possible comparator in this appraisal. He has also worked for the Scottish Medicines Consortium on multiple projects. Ed Wilson has no conflicts of interest to declare.